Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18232445 | 0.86 | TP53BP1 (0.70) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL10080947 | 0.86 | TP53BP1 (0.70) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL30277616 | 0.84 | TP53BP1 (0.67) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL21345718 | 0.84 | TP53BP1 (0.67) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL104557 | 0.84 | TP53BP1 (0.67) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL104339 | 0.83 | HPGD (0.71) | TP53BP1SMN1; SMN2KMT2AHSD17B10HPGD | |
| SCHEMBL11994348 | 0.82 | TP53BP1 (0.65) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL20646759 | 0.81 | TP53BP1 (0.64) | TP53BP1SMN1; SMN2KMT2AGAAHSD17B10 | |
| SCHEMBL12305721 | 0.81 | TP53BP1 (0.64) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL30277542 | 0.80 | TP53BP1 (0.62) | TP53BP1SMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TP53BP1 721/4885SMN1; SMN2 1476/4885NPC1 2354/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TP53BP1 721/4885SMN1; SMN2 1476/4885NPC1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.